Navigation Links
Nexcelom Bioscience to Distribute FCS Express 4 Cytometry Software with Cellometer Vision CBA Instruments

LOS ANGELES, Oct. 11, 2011 /PRNewswire/ -- De Novo Software™, a leading provider of flow and image cytometry data analysis solutions, and Nexcelom Bioscience, a leading supplier of cell counting and analysis products for bioresearch and drug discovery, announced today a licensing agreement enabling Nexcelom to distribute De Novo Software's flagship product, FCS Express 4 Software.  

Under the terms of the agreement, Nexcelom will distribute the FCS Express 4 Cytometry Software to customers in the research, biotech and pharmaceutical markets worldwide.  The FCS Express 4 Software can natively import Nexcelom Cellometer® Vision data for visualization of multi-parametric results.  

With the Cellometer Vision CBA Analysis System, a drop-down menu of assays with pre-set optical module selection, exposure time, and data calculation/presentation set-up make imaging and analysis simple and repeatable. With just 20 Microlitres of sample and a few clicks, users obtain fluorescent cell images, dot plots, and histograms in pre-optimized layouts for specific cell-based assays. Researchers can view cell morphology real-time and archive cell images along with comprehensive analysis reports.

According to Jean Qiu, CTO at Nexcelom, "FCS Express 4 is helping us to improve the overall end-user experience, enabling scientists to focus less on the plotting and formatting process and more on results. We are excited to offer a simple, microscopy-based platform for cell-based assays as an alternative to more complex fluidic instruments."

De Novo Software launched FCS Express 4 in January of 2011.  In addition to fully customized analysis and reporting, the new software adds the ability to analyze image based data.  These novel tools significantly improve assay development, workflow, and enable rapid report generation with image based assays.

David Novo, De Novo Software's president said: "This is an exciting collaboration and business relationship.  We look forward to providing options for flexible data analysis and reporting platform for the Nexcelom Cellometer® Vision customers."

Peter Li, CEO at Nexcelom said: "Seamless integration of FCS Express 4 provides state-of-the-art data reporting and applications support for the Cellometer cell based assays.  De Novo Software is a key strategic partner in our continued effort to provide total solutions to simplify current work flows for our customers."

Michael Sjaastad, Director of Business Development at De Novo Software commented, "There is an unmet need for a common analysis platform for all cytometry data.  We look forward to building upon this key relationship to provide a general platform for data analysis and report generation used by scientists worldwide."

For more information, visit or

SOURCE De Novo Software
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
2. Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman
3. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
4. Roka Bioscience Initiates External Trial for AOAC Certification
5. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
6. OBNs 2011 Annual Awards Dinner Celebrates UK Bioscience Success Stories
7. HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College
8. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
9. Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
10. BD Biosciences Announces Winners of Research Grant Program
11. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):